Immunology and Biotherapies
26.7K views | +12 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Immunotherapy in colorectal cancer: rationale, challenges and potential

Immunotherapy in colorectal cancer: rationale, challenges and potential | Immunology and Biotherapies | Scoop.it
Ganesh et al. describe the rationale for using immunotherapy in select patients with colorectal cancer, discuss clinical findings supporting its use and highlight current strategies and future directions for expanding the scope of immunotherapy in this disease.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Replacing clean rooms, Sheba hospital to use pods to grow cancer-killing cells | The Times of Israel

Replacing clean rooms, Sheba hospital to use pods to grow cancer-killing cells | The Times of Israel | Immunology and Biotherapies | Scoop.it
Ramat Gan medical center hospital to test and refine Cocoon system developed by Switzerland's Lonza Group to fast-track production of CAR-T immunotherapy...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex

Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4–MyD88 Complex | Immunology and Biotherapies | Scoop.it
KEY POINTS DMF suppresses cytokine production in pDCs. DMF blocks Myddosome formation by disrupting the MyD88–IRAK4 interaction. DMF blocks the MyD88–IRAK4 interaction by targeting C13 in IRAK4. Abstract Dimethyl fumarate (DMF) is a prescribed treatment for multiple sclerosis and has also been used to treat psoriasis. The electrophilicity of DMF suggests that its immunosuppressive activity is related to the covalent modification of cysteine residues in the human proteome. Nonetheless, our understanding of the proteins modified by DMF in human immune cells and the functional consequences of these reactions remains incomplete. In this study, we report that DMF inhibits human plasmacytoid dendritic cell function through a mechanism of action that is independent of the major electrophile sensor NRF2. Using chemical proteomics, we instead identify cysteine 13 of the innate immune kinase IRAK4 as a principal cellular target of DMF. We show that DMF blocks IRAK4–MyD88 interactions and IRAK4-mediated cytokine production in a cysteine 13–dependent manner. Our studies thus identify a proteomic hotspot for DMF action that constitutes a druggable protein–protein interface crucial for initiating innate immune responses. Footnotes This work was supported by the National Institutes of Health (Grant CA231991), a Life Science Research Foundation fellowship (to E.V.V.), the American Cancer Society (Fellowship PF-15-142-01-CDD to B.W.Z.), the National Science Foundation (Fellowship DGE-1346837 to M.M.B.), and The Donald E. and Delia B. Baxter Foundation Faculty Scholar Grant (to J.R.T.). The online version of this article contains supplemental material. Received December 26, 2018. Accepted February 26, 2019. Copyright © 2019 by The American Association of Immunologists, Inc.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Genomic correlates of response to immune checkpoint blockade

Genomic correlates of response to immune checkpoint blockade | Immunology and Biotherapies | Scoop.it
Responders and non-responders to cancer immunotherapy can be identified through a range of genomic markers.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Gene and Cell-based Treatments | BioViva Science

Gene and Cell-based Treatments | BioViva Science | Immunology and Biotherapies | Scoop.it
BioViva is an innovative platform working in the development of gene and cell-based treatments for the better health and well-being of people.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Academic, Foundation, and Industry Collaboration in Finding New Therapies | NEJM

Review Article from The New England Journal of Medicine — Academic, Foundation, and Industry Collaboration in Finding New Therapies...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges

Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges | Immunology and Biotherapies | Scoop.it
It is often not the lack of a cure, but the lack of will. Many great strides have been made with diabetes, when people stopped trying to develop medicines, and instead focused on how to enable the body to produce insulin.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Multifaceted B Cell Response in Allergen Immunotherapy

The Multifaceted B Cell Response in Allergen Immunotherapy | Immunology and Biotherapies | Scoop.it
Abstract
While allergen immunotherapy (AIT) for IgE-mediated diseases holds curative potential, the considerable heterogeneity in clinical outcomes may relate to the complex mechanisms of tolerance. The regulation of humoral immunity by AIT contributes to the suppression of allergic responses. Recent findings have revealed novel roles for IgA and IgG antibodies in the induction of tolerance. These mechanisms synergize with their ability to block allergen-IgE binding and mediate inhibitory signaling of effector cells of the allergic response. In addition, the regulatory activity of B cells in AIT extends beyond IL-10 secretion and induction of IgG4. Here, we review the evolution of the B cell response during AIT with special emphasis on the novel protective mechanisms entailing humoral immunity.

Keywords
B cell immunity Allergen immunotherapy Blocking IgG antibodies IgA response B regulatory cells Allergy 
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy. - PubMed - NCBI

Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Protein Pept Lett. 2019 Mar 11. doi: 10.2174/0929866526666190311163820.[Epub ahead of print]...
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. - PubMed - NCBI

Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Biol Chem. 2019 Jan 9. pii: /j/bchm.ahead-of-print/hsz-2018-0338/hsz-2018-0338.xml. doi: 10.1515/hsz-2018-0338.[Epub ahead of print]...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
Scoop.it!

Y-mAbs Therapeutics: Impressive Data In Multiple Oncology Indications, Regulatory Submissions Loom - Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Y-mAbs Therapeutics: Impressive Data In Multiple Oncology Indications, Regulatory Submissions Loom - Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) | Immunology and Biotherapies | Scoop.it
Shares have risen by over 25% since IPO pricing in September of last year.Given indications of severe unmet need and drastically improved patient outcomes, I'm...

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Richard Smith: Who is most likely to have side effects to flu vaccination?

Richard Smith: Who is most likely to have side effects to flu vaccination? | Immunology and Biotherapies | Scoop.it
A simple question that seems to be unanswered but should be answered, says Richard Smith I don’t think that I’ve ever had the flu, certainly nothing that affected me for [...]More...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer | Immunology and Biotherapies | Scoop.it
Immune checkpoint blockade against programmed cell death 1 (PD-1) and its ligand PD-L1 often induces durable tumor responses in various cancers, including non–small cell lung cancer (NSCLC). However, therapeutic resistance is increasingly observed, and the mechanisms underlying anti–PD-L1 (aPD-L1) antibody treatment have not been clarified yet. Here, we identified two unique secreted PD-L1 splicing variants, which lacked the transmembrane domain, from aPD-L1–resistant NSCLC patients. These secreted PD-L1 variants worked as “decoys” of aPD-L1 antibody in the HLA-matched coculture system of iPSC-derived CD8 T cells and cancer cells. Importantly, mixing only 1% MC38 cells with secreted PD-L1 variants and 99% of cells that expressed wild-type PD-L1 induced resistance to PD-L1 blockade in the MC38 syngeneic xenograft model. Moreover, anti–PD-1 (aPD-1) antibody treatment overcame the resistance mediated by the secreted PD-L1 variants. Collectively, our results elucidated a novel resistant mechanism of PD-L1 blockade antibody mediated by secreted PD-L1 variants.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors

Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors | Immunology and Biotherapies | Scoop.it
Immunotherapy with immune-checkpoint inhibitors (ICIs) is a new pillar in the treatment of cancer but can a have range of immune-related adverse effects, including some rare neurological toxicities that constitute paraneoplastic neurological syndromes (PNSs). In this Review, the authors provide an overview of PNSs, the associations of these conditions with ICI therapy and recommendations for the prevention and management of ICI-associated PNSs.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The story of GARP: A potential target for cancer immunotherapy

The story of GARP: A potential target for cancer immunotherapy | Immunology and Biotherapies | Scoop.it
Researchers reveal how the cell surface receptor GARP plays a role in T regulatory cell function and migration to the gut. Because the presence of T regulatory cells in the gut is generally associated with negative outcomes in patients with colorectal cancer, GARP could have potential as a...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The Story of GARP: A Potential Target For Cancer Immunotherapy

The Story of GARP: A Potential Target For Cancer Immunotherapy | Immunology and Biotherapies | Scoop.it
Researchers at the Medical University of South Carolina report findings suggesting that GARP could be a potential new target for immunotherapy directed against colorectal cancer.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome

Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome | Immunology and Biotherapies | Scoop.it
A new form of insulin-dependent diabetes has been recognised, occurring in patients
with cancers who are treated with checkpoint inhibitors. Checkpoint inhibitors are monoclonal antibodies that block checkpoint molecules—such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Working together - CAR T-cell logistics | VJHemOnc

Working together - CAR T-cell logistics | VJHemOnc | Immunology and Biotherapies | Scoop.it
The complexities of CAR T-cell therapy logistics and the union required between industry and clinicians to ensure the best outcomes for patients is discussed by Antonio Pagliuca, MBBS King's College NHS Foundation Trust, London, London, UK, at the 1st European CAR T-Cell Meeting, held in Paris,...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cancers | Free Full-Text | Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

Cancers | Free Full-Text | Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features | Immunology and Biotherapies | Scoop.it
The broader use of immune checkpoint blockade in clinical routine challenges clinicians in the diagnosis and management of side effects which are caused by inflammation generated by the activation of the immune response. Nearly all organs can be affected by immune-related toxicities. However, the most frequently reported are: fatigue, rash, pruritus, diarrhea, nausea/vomiting, arthralgia, decreased appetite and abdominal pain. Although these adverse events are usually mild, reversible and not frequent, an early diagnosis is crucial. Immune-related pulmonary toxicity was most frequently observed in trials of lung cancer and of melanoma patients treated with the combination of the anti-cytotoxic T lymphocyte antigen (CTLA)-4 and the anti-programmed cell death-1 (PD-1) antibodies. The most frequent immune-related adverse event in the lung is represented by pneumonitis due to the development of infiltrates in the interstitium and in the alveoli. Clinical symptoms and radiological patterns are the key elements to be considered for an early diagnosis, rendering the differential diagnosis crucial. Diagnosis of immune-related pneumonitis may imply the temporary or definitive suspension of immunotherapy, along with the start of immuno-suppressive treatments. The aim of this work is to summarize the biological bases, clinical and radiological findings of lung toxicity under immune checkpoint blockade, underlining the importance of multidisciplinary teams for an optimal early diagnosis of this side effect, with the aim to reach an improved patient care.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells

Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells | Immunology and Biotherapies | Scoop.it
Purpose: Inducible caspase 9 ( iCasp9 ) is a cellular safety switch that can make T-cell therapy safer. The purpose of this phase I trial was to investigate the use of iCasp9 -transduced T-cell addback in adult patients undergoing haploidentical stem cell transplantation for high-risk hematologic...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Roles of NKT cells in cancer immunotherapy. - PubMed - NCBI

Roles of NKT cells in cancer immunotherapy. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Arch Pharm Res. 2019 Mar 11. doi: 10.1007/s12272-019-01139-8.[Epub ahead of print] Review...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Rejection of transplanted organs: Long-awaited structure offers new insights

Rejection of transplanted organs: Long-awaited structure offers new insights | Immunology and Biotherapies | Scoop.it
The consequences of organ rejection in transplant patients can be devastating. Professor A. Vathsala, co-director of the National University Centre for Organ Transplantation at the National University Hospital (NUH) and professor ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Innate Immune Signaling Organelles Display Natural and Programmable Signaling Flexibility

Innate Immune Signaling Organelles Display Natural and Programmable Signaling Flexibility | Immunology and Biotherapies | Scoop.it
Innate immune signaling complexes are multifunctional organizing centers that can
be rewired to induce user-defined cellular outcomes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation

Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation | Immunology and Biotherapies | Scoop.it
Article...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A Wide Net to Trap Cancer –

A Wide Net to Trap Cancer – | Immunology and Biotherapies | Scoop.it
Spranger knows that new labs such as hers, which opened in July 2017 at the Koch Institute for Integrative Cancer Research at MIT, face distinct advantages and disadvantages when it comes to making their mark. While younger labs typically have startup grants, they lack the long-term funding, track record, and name recognition of established researchers; on the other hand, new labs tend to have smaller, close-knit teams open to tackling a wider array of investigative avenues to see what works, what doesn’t work, and where promise lies.
more...
No comment yet.